MNTS Stock: $76M Cash, No Debt, and the Ownership Test
Momentus says its cash position has jumped to about $76 million with no debt. The real question is whether Vigoride progress can become revenue before share-count math absorbs the upside.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
10Results6Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
DVLT June 2026 deep dive: the $2B headline is not the thesis yetXORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing risk
Top Tickers
Popular Tags
Results
Save searchLatest indexed results
Showing public results only.
DVLT $2B HELMEX Mystery: Is the Address Really the Red Flag?
A beginner-friendly, fact-based DVLT brief on HELMEX, the UK address controversy, the non-binding $2B term sheet, the $25M payment, dilution, and board rights.
OpenDVLT 8-K: $2B headline, $25M cash test
Datavault AI's June 4 Form 8-K turns the structured financing story into a cash, dilution, control, and approval proof gate.
OpenDVLT $2B structured financing explained for beginners
A beginner-friendly translation of Datavault AI's $2.0B structured financing term sheet, including term sheet status, dilution, tranches, the $25M payment, share-value math, and shareholder proof gates.
OpenDVLT institutional flow check: financing signal, not a supply-crunch thesis
A source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenAIDX: OneTest has revenue growth, but the new Nasdaq float is dilution math
20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAudioEye: accessibility SaaS with a debt line hiding inside the growth story
AudioEye sits in a useful corner of software: websites and mobile apps keep needing accessibility testing, monitoring and remediation. The appeal is $41.2 million of ARR, about 78% GAAP gross margin and positive operating cash flow. The catch is that AEYE is still a small, levered company with GAAP losses, customer concentration and litigation expense.
OpenAcme United: the old scissors company quietly turning into a first-aid roll-up
Acme United looks like a sleepy tools business until the filing mix shows first aid at roughly two-thirds of sales, a new My Medic deal, tariff pain, rising debt, and a customer-concentration test.
OpenAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing risk
Official-source baseline for Able View Global using SEC submissions, SEC company facts, the FY2025 Form 20-F, H1 2025 Form 6-K interim statements, December 2025 and March 2026 Forms 6-K, and official peer filings.
OpenDVLT's next test: cash collection, dilution, and real customer proof
A filing-led diligence review of Datavault AI, focused on revenue quality, cash conversion, dilution, tokenization claims, GPU deployment proof, and validation gates.
Open